Cagrilintide (CAG) is a long-acting amylin analog that is being studied for its potential to support appetite regulation and weight management. Amylin is a naturally occurring hormone released alongside insulin after meals that helps signal fullness, slows stomach emptying, and may reduce overall food intake. Cagrilintide works through a different biological pathway than GLP-1 medications, and researchers are investigating its use both alone and in combination with GLP-1 therapies because the two mechanisms may complement one another. 

Potential areas of research include:

• Supports feelings of fullness (satiety)
• May help reduce appetite and portion sizes
• Slows gastric emptying
• Being studied for weight management and metabolic health
• Investigated in combination with GLP-1 therapies for enhanced effects